Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation - Ferris, R L; Lenz, H J; Trotta, A M (Cancer Treat Rev, 2018)